Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process  by Siddiqui, Rafat A. et al.
Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein
phosphatase-mediated process
Rafat A. Siddiqui a;b;*, Laura J. Jenski b, Kristiana Ne¡ a, Kevin Harvey a,
Richard J. Kovacs a, William Stillwell b
a Cellular Biochemistry Laboratory, Methodist Research Institute at Clarian Health, 1701 N. Senate Ave, Indianapolis, IN 46202, USA
b Department of Biology, Indiana University ^ Purdue University at Indianapolis, Indianapolis, IN 46202, USA
Received 28 April 2000; received in revised form 22 August 2000; accepted 3 November 2000
Abstract
Docosahexaenoic acid (DHA) is an omega-3 fatty acid under intense investigation for its ability to modulate cancer cell
growth and survival. This research was performed to study the cellular and molecular effects of DHA. Our experiments
indicated that the treatment of Jurkat cells with DHA inhibited their survival, whereas similar concentrations (60 and 90 WM)
of arachidonic acid and oleic acid had little effect. To explore the mechanism of inhibition, we used several measures of
apoptosis to determine whether this process was involved in DHA-induced cell death in Jurkat cells. Caspase-3, an important
cytosolic downstream regulator of apoptosis, is activated by death signals through proteolytic cleavage. Incubation of Jurkat
cells with 60 and 90 WM DHA caused proteolysis of caspase-3 within 48 and 24 h, respectively. DHA treatment also caused
the degradation of poly-ADP-ribose polymerase and DNA fragmentation as assayed by flow cytometric TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling) assay. These results indicate that DHA induces apoptosis in
Jurkat leukemic cells. DHA-induced apoptosis was effectively inhibited by tautomycin and cypermethrin at concentrations
that affect protein phosphatase 1 (PP1) and protein phosphatase 2B (PP2B) activities, respectively, implying a role for these
phosphatases in the apoptotic pathway. Okadaic acid, an inhibitor of protein phosphatase 2A, had no effect on DHA-
induced apoptosis. These results suggest that one mechanism through which DHA may control cancer cell growth is through
apoptosis involving PP1/PP2B protein phosphatase activities. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
The healing properties of ¢sh oil have long been
acknowledged as bene¢cial to the human body. The
wide ranging e¡ects of this dietary nutrient have
been shown to play instrumental roles in reducing
cardiac ailments such as atherosclerosis, total cardiac
arrhythmia, and coronary heart disease; promoting
normal neurological and ocular development; and
repressing the evolution of cancer [1^5]. Epidemiol-
ogy studies have associated a lower incidence of
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oleic acid; OKA, okadaic acid; PARP, polyadenosine diphos-
phate-ribose polymerase; PP1, -2A, -2B, protein phosphatase-1,
-2A, -2B; SDS^PAGE, sodium dodecyl sulfate^polyacrylamide
gel electrophoresis; TUNEL, terminal deoxynucleotide transfer-
ase-mediated dUTP nick end labeling; TMY, tautomycin
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cancer with dietary ¢sh oil [6^8]. Much research has
attributed all of these bene¢cial e¡ects to ¢sh oil’s
high content of omega-3 fatty acids, speci¢cally do-
cosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA).
Many anticancer drugs exert their in£uence by in-
ducing apoptosis. Apoptosis, or programmed cell
death, is the physiological method through which
unwanted or unneeded cells are eliminated during
development or other biological processes [9]. It is
also an important process in degenerative diseases,
autoimmune disorders, and neoplasia development
[10]. As a genetically regulated mechanism, apoptosis
can occur through many pathways, but is classi¢ed
by several typical cellular and molecular events such
as cell shrinkage, dilation of endoplasmic reticulum,
membrane blebbing, and extensive nuclear fragmen-
tation [9]. Caspases, a family of cysteine proteases,
play a critical role in apoptosis and are responsible
for many of the biochemical and morphological
changes associated with apoptosis [11^14].
It is interesting that DHA prevents apoptosis in
retinal and neuronal cell lines [15,16]. DHA also pro-
tects neuro2A cells from serum-deprivation-induced
apoptosis [15] and prevents spontaneous activation
of the apoptotic pathway in retina photoreceptor
cells grown in vitro [16]. DHA is reported to reduce
sphingosine-induced apoptosis of the myeloid leuke-
mia line HL-60 [17]. In sharp contrast, several other
reports have demonstrated that DHA and EPA in-
duce apoptosis of various normal and cancer cell
lines [18^21]. Dietary supplementation with DHA
(as a pure agent or in ¢sh oil) increased apoptotic
cell death in normal rat colonic cells [22^26], and the
transplantable rat Morris hepatocarcinoma 3924A
[27], exerted suppressive e¡ects on the progression
of human breast cancer cells MDA-MB-231 in athy-
mic nude mice [28,29], increased survival time for
dogs with lymphoma [30], reduced risk of prostate
cancer in humans [31], and signi¢cantly reduced the
incidence of tumor induction by dimethylbenz[a]an-
thracene in rats [32]. Addition of DHA to cultures of
lung carcinoma A427 [33], Hep2 human larynx tu-
mor cells [34], pancreatic Mia-Pa-Ca-2 cells [35], and
embryonal carcinoma Tera-2 cells [36] induced apo-
ptosis in these cell lines. DHA also inhibited growth
of cervical cells immortalized by highly oncogenic
human papillomavirus 16 (HPV16), foreskin kerati-
nocytes immortalized by HPV16, and keratinocytes
grown from papillomas with an HPV etiology [37].
Furthermore, conjugated DHA with a triene struc-
ture has been shown to induce apoptosis in DLD-1
cells (colorectal adenocarcinoma) without any e¡ect
on normal human ¢broblast cell lines [38]. At
present, the cellular and molecular mechanisms of
DHA-induced apoptosis are unclear, and a better
understanding of basic actions of DHA is needed
before this polyunsaturated fatty acid can be fully
employed in the clinic as an anticancer agent [39,40].
Several studies have shown that changes associated
with apoptosis are mediated through activation of
protein phosphatases [41^47]. Wolf and Eastman
[44] have demonstrated that activation of protein
phosphatase 1 (PP1) plays an important role in
Fas-induced apoptosis by stimulating mitochondrial
release of cytochrome c and caspase activation in
HL-60 and Jurkat cells. Similarly, activation of a
PP2A-like phosphatase has been demonstrated to
play a key role in the induction of apoptosis in a
neuronal cell line [43]. Several other studies have
shown that a ceramide activated-protein phosphatase
(CAPP), which is a member of protein phosphatase
2A, is involved in receptor-mediated induction of ap-
optosis in various cell lines [45]. These studies suggest
that protein phosphatase activation may be a com-
mon feature of cells undergoing apoptosis. The
present study was therefore undertaken to explore
the role of protein phosphatases in DHA-induced
apoptosis in Jurkat leukemic cell lines.
2. Materials and methods
2.1. Materials
The Jurkat cell line (Clone E6-1) was obtained
from ATCC (American Type Culture Collection,
Rockville, MD). RPMI 1640 was purchased from
BioWhittaker (Walkersville, MD). Bovine calf serum
(BCS) containing 3.6 g% albumin came from Hy-
Clone Laboratories (Logan, UT). Docosahexaenoic
acid and arachidonic acid were obtained from Nu-
Chek-Prep, (Elysian, MN). Monoclonal anti-caspase-
3 antibody was obtained from Transduction Labora-
tories (Lexington, KY). The polyclonal anti-PARP
antibody and TUNEL £ow cytometry kit were ob-
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tained from Roche/Boehringer Molecular Biochemi-
cals (Indianapolis, IN). The peroxidase-conjugated
anti-mouse and anti-rabbit antibodies, the ECL kit,
hyper¢lm-HP, and the hyper¢lm-ECL X-ray ¢lms
came from Amersham Pharmacia Biotech (Bucking-
hamshire, UK). BCA Protein Assay kit came from
Pierce (Rockford, IL). The pre-cast 12.5% SDS^
PAGE gels were acquired from Owl Separation Sys-
tems (Portsmouth, NH). The polyvinylidene di£uor-
ide (PVDF) membranes were supplied from Milli-
pore (Bedford, MA). Okadaic acid, tautomycin,
and cypermethrin came from Calbiochem^Novabio-
chem, San Diego, CA. Permethrin and caspase-3 in-
hibitor DEVD-CHO (N-acetyl-Ala-Ala-Val-Ala-Leu-
Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Asp-
Glu-Val-Asp-CHO, aldehyde) came from Biomol
Research Laboratories (Plymouth Meeting, PA).
Oleic acid and all chemicals and reagents used to
prepare bu¡ers and solutions herein mentioned
were supplied by Sigma (St. Louis, MO).
2.2. Cell culture
The Jurkat T-cell leukemia cells were grown in
RPMI 1640, supplemented with 100 units/ml of pen-
icillin, 100 Wg/ml of streptomycin, 2 mM glutamine,
and 2% bovine calf serum. The cells were kept in a
humidi¢ed atmosphere of 37‡C and 5% CO2. Cell
viability was determined by trypan blue exclusion.
The Jurkat cells were treated with various concentra-
tions of DHA, AA, or OA. DHA and AA were dis-
solved in ethanol, so that the ¢nal concentration of
ethanol in culture medium did not exceed 0.05%.
Oleic acid was suspended into medium prior to use.
All fatty acid stocks were stored in small aliquots at
370‡C under nitrogen, as described, to prevent their
degradation and/or oxidation [48]. The working so-
lutions of fatty acids were freshly prepared each time
prior to their use.
2.3. Western blotting
After incubation, the cells were lysed with 50 Wl of
lysis bu¡er containing 20 mM Tris^HCl (pH 8), 137
mM NaCl, 100 mM NaF, 2 mM Na3VO4, 10% v/v
glycerol, 1% v/v Nonidet P-40, 2 mM PMSF, 1 mg/
ml leupeptin, 0.15 units/ml aprotinin, and 2.5 mM
DIFP for 10 min on ice. Protein concentrations in
the cell lysate were measured with a BCA protein
assay system (Pierce), and equal amounts of deter-
gent-solubilized protein extracts were resolved on
12.5% SDS^polyacrylamide gels as described previ-
ously [49]. The resolved proteins were electrophoreti-
cally transferred onto a PVDF membrane. Residual
binding sites on the membranes were blocked with
TTBS (50 mM Tris^HCl (pH 7.4), 150 mM NaCl,
0.05% Tween-20) containing 2% bovine serum albu-
min (BSA). The blots were then incubated with pri-
mary antibody (anti-caspase-3 or anti-PARP, 1:1000
in 1% BSA in TTBS) for 1 h at room temperature.
The membranes were then washed with TTBS
and incubated with peroxidase-conjugated anti-
mouse or anti-rabbit IgG (1:1000 dilution in 1%
BSA in TTBS). Blots were ¢nally developed using
an enhanced-chemiluminescence (ECL) kit and
ECL x-ray ¢lm.
2.4. TUNEL £ow cytometry assay
TUNEL (terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling) assay was per-
formed by using an In Situ Cell Death Detection
kit (Roche/Boehringer Molecular Biochemicals) as
recommended by the manufacturer. Brie£y, after in-
cubation with DHA, the cells (1U105/100 Wl) were
¢xed by adding 200 Wl of 1% paraformaldehyde so-
lution and incubated for 30 min at room tempera-
ture. These cells were washed once in phosphate-
bu¡ered saline (PBS) and then suspended in 100 Wl
of permeabilization solution (0.1% Triton X-100 in
0.1% sodium citrate) for 2 min on ice. The cells were
then washed twice with PBS and incubated with the
TUNEL reaction mixture, as supplied by the manu-
facturer, in a humidi¢ed, dark, 37‡C atmosphere for
1 h. The cells were then washed and analyzed using a
Becton^Dickinson FACStarPLUS £ow cytometer (San
Jose, CA) equipped with a 488-nm wavelength argon
laser operated at 200 mW. The £uorescein was de-
tected through a 530 þ 20 band-pass ¢lter.
2.5. Protein labeling with [32P]ortho-phosphate
Jurkat cells (3U106/ml) were washed twice with
serum and phosphate-free RPMI (Gibco, Life Tech-
nologies) and incubated with [32P]ortho-phosphate
(100 WCi/ml) for 3 h. Cells were washed with
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RPMI containing 2% BCS 3 times to remove unin-
corporated label. The radiolabeled cells (1U105/ml)
were then incubated with 60 WM DHA. After each
incubation time, cells were lysed with 50 Wl lysis bu¡-
er, their protein contents were determined, and equal
amounts of protein from each sample were resolved
on a 7.5% SDS^polyacrylamide gel as described
above. The resolved proteins were transferred on a
PVDF membrane and then stained with a reversible
Amido Black stain (Sigma) to determine the pattern
of the resolved proteins. The same blot was then
subjected to autoradiography using Amersham Hy-
per¢lm MP for overnight exposure to determine the
pattern of phosphorylated/dephosphorylated pro-
teins.
3. Results
3.1. E¡ect of fatty acids on survival of Jurkat
leukemic cells
Cells cultured in the presence of various concen-
trations of fatty acids (0^90 WM) for incubation
times ranging from 0 to 48 h showed di¡erent via-
bility trends depending on which fatty acid was used.
As shown in Fig. 1a, low concentrations of DHA (30
WM) had no e¡ect on cell viability; however, higher
concentrations (60 and 90 WM) for extended periods
of incubation time (24 and 48 h) markedly decreased
the viability of the cells. The lowest cell viability,
28%, was produced by 90 WM DHA after 48 h of
incubation. In contrast to these results, AA had little
e¡ect on Jurkat cell viability (Fig. 1b). The maximum
concentration of AA (90 WM) with the longest incu-
bation time (48 h) reduced Jurkat cell viability by
only 20% compared to the control cells. As illus-
trated in Fig. 1c, OA also did not substantially a¡ect
Jurkat cell survival. These results clearly demon-
strated that destruction of Jurkat leukemic cells is
enhanced by DHA compared to AA and OA. In
subsequent experiments, we studied whether the de-
struction of Jurkat cells in the presence of DHA is
due to induction of apoptosis.
C
Fig. 1. E¡ects of oleic acid, arachidonic acid, and docosahexae-
noic acid on cell viability. Jurkat cells (1U105/ml) were incu-
bated in the presence of (b) 0 WM, (S) 30 WM, (F) 60 WM,
and (8) 90 WM concentrations of (a) docosahexaenoic acid,
(b) arachidonic acid, or (c) oleic acid for di¡erent time periods
in a 37‡C incubator as described in the text. Control cells were
incubated with similar amounts of solvent used to dissolve these
fatty acids. After each incubation time, cell viability was as-
sayed by determining the trypan blue dye exclusion. Results
represent mean þ S.E.M. for the 3 experiments.
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3.2. DHA treatment of Jurkat cells induces caspase-3
activation
Caspase-3 belongs to a family of cysteine proteases
that are involved downstream in the process of apo-
ptosis. Caspases in cells are present as inactive pro-
enzymes, which undergo proteolytic cleavage to be-
come active enzymes. Fig. 2 demonstrates a DHA
dose- and time-dependent induction of caspase-3 ac-
tivation in Jurkat cells, i.e., the intensity of the cas-
pase-3 band seen at 35 kDa is decreased and that of
the 18 kDa processed form increased as the DHA
concentration and incubation time increased. This
¢nding was further con¢rmed when cells were prein-
cubated with a highly speci¢c and cell permeable
caspase-3 inhibitor. The results presented in Fig. 3
demonstrate that pre-treatment of cells with caspase-
3 inhibitor signi¢cantly (P6 0.001, Students’ t-test)
improved the viability of cells from 61% (untreated
cells) to 88% (treated cells). These ¢ndings suggest
that DHA may a¡ect the survival of Jurkat cells by
inducing events upstream, leading to the activation
of caspase-3, and ultimately leading to cell death.
3.3. DHA treatment induces PARP proteolysis in
Jurkat cells
Because of the notable relation between DHA-in-
duced cell death and caspase-3 activation, we further
explored the e¡ect of DHA on indicators of apopto-
sis. One of the direct substrates of caspase-3 is poly-
Fig. 3. E¡ect of caspase-3 inhibitor on cell survival. Cells
(1U105/ml) were preincubated with DEVD-CHO (caspase-3 in-
hibitor) for 30 min and then exposed to vehicle (black bars) or
60 WM DHA (white bars) for 48 h. Cell viability was assayed
by determining the trypan blue exclusion. Results represent
mean þ S.E.M. for three experiments. ***P6 0.001, Student’s t-
test, relative to the ‘no caspase-3 inhibitor’ control group.
Fig. 2. Docosahexaenoic acid activates caspase-3 by proteolytic degradation. Cells (1U105/ml) were grown in the presence or absence
of various concentrations of DHA as described in the text. After each incubation, cells were lysed and then subjected to protein sepa-
ration on a 12.5% SDS^PAGE. The caspase-3 bands were detected by Western immunoblotting using anti-caspase antibodies (1:1000
dilution in Tris bu¡er saline (pH 8.0) containing 1% fetal calf serum) and the ECL-chemiluminescence method.
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adenosine diphosphate-ribose polymerase (PARP),
which is cleaved during apoptosis from 113 kDa to
89 and 24 kDa fragments. The results shown in Fig.
4 demonstrate the cleavage of PARP upon exposure
to DHA. The 89 kDa subunit is apparent within 24 h
of incubation in 90 WM DHA and by 48 h of incu-
bation in 60 WM DHA. The 24 kDa fragment of
PARP proteolysis was not detected by the anti-
PARP antibodies. These data imply that activation
of caspase-3 by DHA in Jurkat cells results in deg-
radation of PARP enzymes.
3.4. DHA-Treated cells show DNA fragmentation as
reported by TUNEL assay
The hypothesis that DHA induces apoptosis in
Jurkat cells was further investigated by testing one
of the hallmarks of apoptosis, DNA fragmen-
tation. DHA-induced DNA fragmentation was mea-
sured on an individual cell basis using £ow cytome-
try; £uorescence intensity is directly proportional to
the degraded DNA present within each cell. The
upper panel of Fig. 5 provides the raw £ow cyto-
metric data and also shows the gates established to
calculate the percent of cells undergoing apoptosis
(i.e., with £uorescence above the negative control).
The lower panel of Fig. 5 shows summarized data
illustrating the DHA dose-dependent increase in
DNA fragmentation (mean £uorescent intensity) ap-
parent after 48 h of DHA exposure. These results
suggest that approximately 70% of the Jurkat cells
treated with 90 WM DHA for 48 h undergo apopto-
sis.
3.5. DHA-Induced cell destruction is mediated
through protein phosphatase activation
To explore our hypothesis that protein phospha-
tases are involved in DHA-induced apoptosis, we
incubated Jurkat cells in the presence of various ser-
ine/threonine phosphatase (PP1, PP2A, PP2B) inhib-
itors during DHA-induced apoptosis. Results shown
in Fig. 6 indicate that 10 nM okadaic acid (OKA), a
concentration known to inhibit PP2A, did not signif-
icantly improve cell viability during 24 or 48 h of
incubation with DHA. In contrast, 10 nM tautomy-
cin (TMY) or 500 pM cypermethrin (CMT) in con-
centrations that e¡ectively block PP1 or PP2B, re-
spectively, reduced DHA-induced destruction of
Jurkat cells (P6 0.001, Student’s t-test). The role of
protein phosphatases PP1 and PP2B in the preven-
tion of DHA-induced cell destruction was further
analyzed by using other active and inactive ana-
logues of protein phosphatase inhibitors. Results
demonstrated that phosphatidic acid, a highly selec-
tive inhibitor of PP1 [50], e¡ectively blocked cell de-
struction by DHA, whereas lysophosphatidic acid, a
structurally similar but inactive compound for PP1,
did not prevent DHA-induced cell destruction (Table
1). Similarly, permethrin, an inactive structural ana-
logue of cypermethrin (PP2B inhibitor), had no e¡ect
on DHA-induced cell destruction. Furthermore,
phosphatidic acid also prevented pro-caspase-3 cleav-
age and PARP degradation (unpublished results).
Moreover, DHA-induced activation of phosphatases
is also evident from results shown in Fig. 7. These
data clearly demonstrated that DHA caused activa-
Fig. 4. Induction of polyadenosine diphosphate-ribose polymerase (PARP) degradation by docosahexaenoic acid. Cells (1U105/ml)
were grown in the presence or absence of various concentrations of DHA as described in the text. After each incubation, cells were
lysed and then subjected to protein separation on a 12.5% SDS^PAGE. The separated proteins were then blotted onto a PVDF mem-
brane. The PARP bands were detected by Western immunoblotting using anti-PARP antibodies (1:1000 dilution in Tris bu¡er saline
(pH 8.0) containing 1% fetal calf serum) and ECL-chemiluminescence method.
BBAMCR 14712 5-1-01
R.A. Siddiqui et al. / Biochimica et Biophysica Acta 1499 (2001) 265^275270
tion of cellular phosphatases, which results in de-
phosphorylation of several cellular proteins, as evi-
dent on the autoradiograph (Fig. 7B). These data
also demonstrate that the lower intensities of phos-
phorylated protein in the presence of DHA are not
due to di¡erent amounts of proteins in di¡erent lanes
(Fig. 7A). In sum, these results suggest DHA causes
activation of cellular phosphatases and that PP1- and
Table 1




(3) DHA (+) DHA
Control
Without serum 95 þ 5 37 þ 10***
With serum (2%) 95 þ 4 64 þ 6***
Active inhibitors analogues
25 WM phosphatidic acid* (PP1) 95 þ 2 76 þ 8NS
500 pM cypermethrin (PP2B) 96 þ 4 84 þ 5NS
Inactive inhibitors analogues
25 WM lysophosphatidic acid* (PP1) 82 þ 5 6 þ 1***
500 pM permethrin (PP2B) 88 þ 5 38 þ 5***
*Cells (1U105/ml) were grown in the absence of serum with
15 WM DHA and active or inactive inhibitors of PP1 for 2 h or
in the presence of 2% bovine calf serum with 60 WM DHA for
48 h with active or inactive inhibitors of PP2B. Cell viability
was measured by the trypan blue exclusion assay. The results
are mean þ S.E.M. for 3 experiments. Results are analyzed by
Student’s t-test, relative to the (3) DHA group: ***P6 0.001;
NS, not signi¢cant.
Fig. 6. E¡ects of protein serine/threonine phosphatase inhibitors
on DHA-induced cell survival. Cells (1U105/ml) were grown in
the presence (gray bars) or absence (black bars) of 60 WM
DHA for 48 h in the presence of either vehicle (control) or 10
nM okadaic acid, 10 nM tautomycin, or 500 pM cypermethrin.
Cell viability was measured using trypan blue exclusion assay.
The results are mean þ S.E.M. for 4 experiments. ***P6 0.001;
NS, not signi¢cant: Student’s t-test, relative to the ‘no treat-
ment’ control group.
Fig. 5. TUNEL assay for measuring DHA-induced apoptosis.
Cells (1U105/ml) were grown with varying concentrations of
DHA (0^90 WM) for 0^48 h as described in the text. TUNEL
assay was performed by using an In Situ Cell Death Detection
kit (Boehringer Mannheim) as recommended by the manufac-
turer. The cells were then analyzed using a Becton^Dickinson
FACStarPLUS £ow cytometer (San Jose, CA) equipped with a
488-nm wavelength argon laser operated at 200 mW. The £uo-
rescein was detected through a 530 þ 20 band-pass ¢lter. (A)
Raw cytometric data indicating gates (M1 and M2) established
using an unlabeled control to calculate the percentage of cells
undergoing apoptosis. (B) Summarized data from A.
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PP2B-type protein phosphatases play a role in DHA-
induced cell destruction.
3.6. Activation of caspase-3 and degradation of PARP
are prevented by PP1 and PP2B inhibitors
To study whether prevention of DHA-induced cell
destruction by PP1 and PP2B inhibitors is due to
their e¡ects on the process of apoptosis, we assayed
caspase-3 and PARP degradation in Jurkat cells.
Consistent with the data on cell viability shown in
Fig. 8, OKA weakly prevented DHA-induced pro-
caspase-3 cleavage (36% control vs. 44% treated),
whereas TMY (36% control vs. 68% treated) and
CMT (36% control vs. 70% treated) e¡ectively pre-
vented pro-caspase-3 cleavage, and hence, activation
of caspase-3 (Fig. 8a). Similarly, TMY (23% control
vs. 80% treated) and CMT (23% control vs. 98%
treated) also inhibited the degradation of PARP
(Fig. 8b), a substrate of caspase-3, whereas OKA
Fig. 8. E¡ect of protein serine/threonine phosphatase inhibitors
on caspase-3 and PARP degradation. Cells (1U105/ml) were
grown in the presence (gray bars) or absence (black bars) of 60
WM DHA and treated with either vehicle (control), 10 nM oka-
daic acid, 10 nM tautomycin, or 500 pM cypermethrin as de-
scribed in the legend to Fig. 6. After each incubation, cells
were lysed and then subjected to protein separation on a 12.5%
SDS^PAGE. The separated proteins were blotted onto a PVDF
membrane and immunoblotted. The caspase-3 or PARP bands
were detected by Western immunoblotting using (a) anti-cas-
pase-3 or (b) anti-PARP antibodies and ECL-chemilumines-
cence method. Amounts of procaspase-3 and non-degraded
PARP were quanti¢ed by densitometric analysis using an HP
ScanJet 4C scanner and Intelligent Quanti¢er software (Bio-
image Systems, Ann Arbor, MI). The results of DHA-treated
values (grey bars) are relative to non-DHA-treated values
(black bars).
Fig. 7. E¡ect of DHA on cellular protein phosphorylation.
Cells were labeled with [32P]ortho-phosphate as described in the
text. Radiolabeled cells (1U105/ml) were incubated with 60 WM
DHA for indicated time periods. Proteins were resolved on a
7.5% SDS^polyacrylamide gel. The resolved proteins were
transferred on a PVDF membrane and then stained with amido
black to determine the pattern of resolved proteins (A). The
same blot was subjected to autoradiography to determine the
pattern of phosphorylated or dephosphorylated proteins (B).
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weakly prevented PARP degradation (23% vs. 38%)
in Jurkat cells incubated with DHA. These results
strongly implicate PP1- and PP2B-like protein phos-
phatases in DHA-induced apoptosis.
4. Discussion
In this study we demonstrate that DHA induces
apoptosis in a human leukemic cell line and suggest
that this fatty acid mediates its e¡ects through acti-
vation of protein serine/threonine phosphatases. Cell
viability using trypan blue exclusion assay, a widely
used procedure in apoptosis studies [51,52], was ini-
tially used to examine the cytotoxic e¡ects of DHA
on Jurkat cells. However, other assays (caspase-3
activation, PARP degradation, DNA fragmentation)
were used to demonstrate apoptosis as an end result
of exposure to cytotoxic DHA in vitro. Our failure
to see the cytotoxic e¡ects of OA and AA on Jurkat
cells compared to DHA under identical conditions
may be due to either a direct e¡ect of DHA on
Jurkat leukemic cells or due to the di¡erences in
the uptake of these fatty acids or the rate of their
degradation. These di¡erences were not investigated
in the present study as they are beyond the scope of
this study. However, our results demonstrate that cell
viability and cell apoptosis were una¡ected by low
concentrations of DHA and short incubation times,
suggesting that pharmacological doses of DHA,
achieved at the site of tumor growth, may be ther-
apeutic, whereas lower doses are non-toxic. In the
present investigation, ethanol was used instead of
albumin to deliver DHA to cells. The concentration
of ethanol did not exceed 0.05%, which was found to
be non-cytotoxic. The amount of serum albumin in
tissue cultures during incubation with DHA was es-
timated to be 10 WM, which gives an albumin:DHA
molar ratio in the range of 1:3 (30 WM DHA) to 1:9
(90 WM DHA). When serum was completely re-
moved, a concentration of 15 WM DHA was found
to be cytotoxic to Jurkat cells (Table 1), which is 4
times less than the e¡ective concentration (60 WM) in
the presence of serum. These results indicate that
serum may act as a reservoir where DHA is present
bound to albumin, and in the absence of serum (al-
bumin), a concentration of DHA 4 times lower is
cytotoxic.
Very little is known about the molecular mecha-
nism through which DHA may be cytotoxic for can-
cer cells. Our results suggest the involvement of
a PP1/PP2B-type protein, serine phosphatase, in
DHA-induced apoptosis of Jurkat cells. However,
it is not clear from the present results if there are 2
di¡erent protein phosphatases involved or a unique
protein phosphatase that is responsive to both PP1
and PP2B inhibitors. These studies also indicate that
this PP1/PP2B-type protein phosphatase acts up-
stream of caspase-3 activation in the sequence of ap-
optotic events. Furthermore, it is also possible that
there are multiple signaling pathways activated
through a parallel PP1 and PP2B activation, con-
verging at a common point. It is not obvious how
DHA in£uences these protein phosphatases. This in-
£uence could be through a direct interaction of DHA
with the regulatory units of these phosphatases or
through generation of 1 or more secondary media-
tors. An important role for sphingoid lipids in the
modulation of cell response to di¡erent extracellular
signals has recently been uncovered, and a number of
studies suggest an important role for ceramide in ap-
optosis [53,54]. It has been shown that ceramide ac-
tivates a speci¢c ceramide-activated protein phospha-
tase (CAPP), which is a member of the protein
phosphatase 2A class of serine/threonine protein
phosphatases [55^57], and that activation of this en-
zyme mediates the induction of apoptosis [57,58].
Furthermore, recent studies report that ceramide
can also induce apoptosis through activation of class
1 protein phosphatase [45]. These ¢ndings, therefore,
suggest a broader role for ceramide in regulating ap-
optosis through the activation of various protein
phosphatases. Ceramide formation occurs in caveo-
lae-like domains in plasma membranes that are rich
in sphingomyelin [58]. Our previous work has indi-
cated that DHA is rapidly incorporated into mem-
brane phospholipids (particularly phosphatidyletha-
nolamines) [59] and then alters membrane structure
and function [60,61]. Our working hypothesis is that
DHA incorporation into Jurkat cells, as investigated
here, may alter membrane microdomains, resulting
in the accumulation of sphingomyelinase into lipid
rafts that are already enriched in cholesterol, satu-
rated fatty acyl chains, and sphingolipids, including
sphingomyelin. Enzymatic degradation of sphingo-
myelin to phosphorylcholine and ceramide would en-
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sue, initiating the apoptosis cascade. This may be
cell-type-speci¢c, however, as DHA did not appear
to a¡ect ceramide-induced apoptosis in HL-60 cells
[17].
One other possible mechanism of DHA-induced
apoptosis in Jurkat cells is through a Fas-mediated
process. Jurkat cells are known to express Fas and
secrete Fas ligands [47,62^66]. It is possible that in-
cubating cells with DHA results in increased expres-
sion of Fas and/or elevated secretion of Fas ligand,
which in turn causes Fas-receptor-mediated apopto-
sis in these cells. However, this possibility is less
likely because our initial experiments did not show
activation of caspase-8, indicating the absence of a
receptor-mediated process (data not shown). Another
possible mechanism of DHA-induced caspase-3 acti-
vation leading to cell apoptosis through PP1/PP2B is
via interaction with mitochondria. Caspase-9 is regu-
lated upstream by the release of cytochrome c from
the mitochondria [44]. The interaction of cytochrome
c with another apoptotic protein, Apaf-1, and dATP
would also lead to caspase-3 activation. Further
studies are clearly needed to explore these possibil-
ities, among others, to determine the true path of
apoptosis induced by DHA.
In conclusion, this research indicates that DHA in
Jurkat leukemic cells induces many of the hallmarks
of apoptosis on cytosolic and nuclear levels. Upon
signi¢cant DHA exposure, cells activate the apopto-
tic caspase-3 enzyme, degrade the DNA repair en-
zyme PARP, and undergo DNA fragmentation as
assayed by TUNEL £ow cytometry analysis. These
processes appear to be regulated upstream by activa-
tion of the PP1A/PP2B class of protein phospha-
tases.
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